trending Market Intelligence /marketintelligence/en/news-insights/trending/uckfsum697-fn5u-rx9o8a2 content esgSubNav
In This List

Indivior's Perseris gets US FDA approval as schizophrenia treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Indivior's Perseris gets US FDA approval as schizophrenia treatment

Indivior PLC said the U.S. Food and Drug Administration approved Perseris, a once-monthly injectable that contains risperidone, for adults with schizophrenia.

Risperidone is an established treatment for schizophrenia, a serious mental disorder that affects a patient's thoughts, emotions and behavior.

Perseris provides patients sustained levels of risperidone over one month via an extended-release delivery system.

The Richmond, Va.-based drugmaker's application was backed by late-stage trial data demonstrating Perseris' efficacy, even without a loading dose or any supplemental oral risperidone.